Equillium, Inc. (EQ)
NASDAQ: EQ · Real-Time Price · USD
0.4405
-0.0395 (-8.23%)
Apr 24, 2025, 4:00 PM EDT - Market closed

Company Description

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States.

Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as well as completed Phase 1b clinical trial to treat systemic lupus erythematosus and lupus nephritis and in phase 2 clinical trial for the treatment of ulcerative colitis.

The company also develops EQ101, first-in-class, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which completed Phase 1/2 to treat cutaneous T cell lymphoma.

It serves its products to gastroenterology, dermatology, hematology, transplant science, rheumatology, pulmonology, and oncology areas.

The company has a collaboration and license agreement with Biocon SA to develop, make, have made, use, sell, have sold, offer for sale, import and otherwise exploit itolizumab (EQ001) and any pharmaceutical composition or preparation containing or comprising itolizumab (EQ001) that uses Biocon technology or Biocon know-how, or collectively, a Biocon Product.

The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017.

Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Equillium, Inc.
Equillium logo
Country United States
Founded 2017
IPO Date Oct 11, 2018
Industry Biotechnology
Sector Healthcare
Employees 35
CEO Bruce Steel

Contact Details

Address:
2223 Avenida De La Playa, Suite 105
La Jolla, California 92037
United States
Phone 858 240 1200
Website equilliumbio.com

Stock Details

Ticker Symbol EQ
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001746466
CUSIP Number 29446K106
ISIN Number US29446K1060
Employer ID 82-1554746
SIC Code 2834

Key Executives

Name Position
Jason A. Keyes Chief Financial Officer
Penny Tom Senior Vice President of Finance and Principal Accounting Officer
Michael Moore Vice President of Investor Relations and Corporate Communications
Dr. Matthew Ritter Ph.D. Senior Vice President of Corporate Development
Joel M. Rothman Chief Development Officer
Dr. Lisette Acevedo Vice President of Clinical Development

Latest SEC Filings

Date Type Title
Apr 24, 2025 8-K Current Report
Apr 10, 2025 ARS Filing
Apr 10, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 10, 2025 DEF 14A Other definitive proxy statements
Mar 28, 2025 PRE 14A Other preliminary proxy statements
Mar 27, 2025 10-K Annual Report
Mar 27, 2025 8-K Current Report
Feb 6, 2025 8-K Current Report
Dec 13, 2024 8-K Current Report
Dec 12, 2024 8-K Current Report